BerGenBio Raises Nok500m (€45.4m) via an Over Subscribed Private Placement
BERGEN, Norway, May 5, 2020 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is pleased to announce that it has raised NOK500m (gross) (€45.4 million) via an over subscribed Private Placement that took place via an accelerated book building process after close of market on 4 May 2020. The Offering was made through the allocation of 13,325,000 shares at a subscription price of NOK 37.50 per share.
Access to content from the Arctic Knowledge Archives is available to Passport holders only.
Arctic Today is a non-profit organization, supported by donations from readers like you. While we strongly believe in giving free access to current news for all readers, we reserve content older than one year for our supporters. All individual contributions of at least $20/month or $150/year will receive a Passport to the Arctic Knowledge Archives. Help us drive the leading non-profit editorial team dedicated to delivering context, information and analysis about events in the Arctic.
Already have a Passport? Sign in
Choose your level of support and unlock your Arctic Today Passport.
- Monthly
- Annually
- Groups & Institutions
Individual Monthly
$20.00
Month
Individual Annual
$150.00
Year
Individual Monthly
$20.00
0
Individual Yearly
$150.00
0
